PDLIM7 and classic Hodgkin lymphoma: The results of our study have shown the presence of the Mediterranean subtype with 30 pb deletion in approximately 28% of patients with cHL, suggesting the need to evaluate the efficacy of the novel and/or developing LMP1-targeted therapies against this high-risk LMP1 variant both during drug development stages and in clinical trials.